William Bracken, PhD, DABT, Head of Toxicology Bill had near 30 years career at AbbVie as a member of the Preclinical Safety Leadership Team where he had scientific/regulatory management responsibilities for the early and late-stage drug development portfolio and marketed products. Bill’s accomplishments include published research in neurobiology, chemical carcinogenesis, hepatotoxicity, heavy metal toxicity, and toxicology in drug development.
Shuang Liu, PhD, Founder & CEO Co-inventor of CSTI-500. 20 years of experience in drug R&D as an integrated project leader. Led Curia’s (formerly AMRI) triple monoamine program and collaboration with a big pharma that delivered 4 NCEs, including CSTI-500, for clinical development. Led other successful discovery programs in CNS, oncology, and autoimmune at Curia. Co-Inventor of >30 patent families. PhD in organic chemistry from the University of Georgia with postdoc training at Emory University.
John Maki, Strategic Advisor 30+ years of management and investment experience in life science. Formerly CEO of Vicus Therapeutics a clinical-stage immuno-oncology company, Managing Director at TDI and Audax Group, Principal at Bain Capital and Consultant at Bain & Company.
Mark Pirner, MD, PhD, Chief Medical Officer Dr Pirner brings extensive R&D leadership and strategic medical positioning to ConSynance. His diverse leadership experiences in discovery research and clinical development span multiple industries and range from early clinical development to NDA approval and subsequent medical affairs business support. Before joining industry Mark completed his endocrinology fellowship at NIH Inter-Institute Endocrinology Fellowship Program (NIDDK division) and internal medicine residency at Duke University Medical Center. He attended the University of Minnesota Medical Scientist Training Program and graduated summa cum laude from St Olaf College. He worked briefly as a private practice physician and Clinical Associate Professor for the University of Wisconsin Medical School after he completed his fellowship.
Al Ritter, PhD, Head of CMC Over 30 years of international drug development and chemical manufacturing experience. His expertise in organic chemistry, regulatory, problem solving skills have allowed him to lead large and small teams to high productivity and success through complex challenges. PhD in Organic Chemistry from the University of Notre Dame. Al has previously held leadership roles at Eli Lilly and Endocyte, Inc.
Lois Rosenberger, PhD, Head of Regulatory President of LBR Regulatory and Clinical Consulting Services. 30+ years of regulatory, quality assurance, and 20+ years of experience in managing clinical trials including for PWS. Lois held regulatory leadership positions at Kendle CRO, Marion-Merrell Dow, and P&G.
Sarah Sheldrick, PhD, Research Director Experienced neuroscience researcher with a background in translational neuroscience research ranging from discovery to qualification of molecular and imaging biomarkers, as well as mechanisms and informatics approaches. PhD in Psychological Medicine from King’s College London. As part of her postdoctoral studies Sarah was the Biomarker Team Leader for the Translational Neuroscience and Dementia Research group at the University of Oxford.